Effectiveness of Home Based Occupational Therapy for Dementia.

Effectiveness of an Optimized Home Based Occupational Therapy for Patients With Dementia.

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00732329

Acronym

ERGODEM

Enrollment

160

Registered

2008-08-12

Start date

2008-08-31

Completion date

2011-01-31

Last updated

2015-02-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dementia

Brief summary

The purpose of this study is to determine if a home based occupational therapy is effective in the treatment of dementia.

Interventions

BEHAVIORALOccupational Therapy

optimized home Based Occupational Therapy including: * diagnostic assessment * patient-centered definition of targets involving the care giver * occupational therapy

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

55 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Dementia (according to DSM-IV TR) 2. A score 26 to 12 on the MMSE 3. Must be 55 or older 4. Patient is living at home or therapeutical flat sharing 5. Primary care giver at least 2 days / week available at home 6. Written informed consent from patient and care giver 7. German as dominant language

Exclusion criteria

1. Other dementia (p.e. frontotemporal dementia, dementia with Lewy Bodies, Creutzfeldt-Jakob disease, Parkinson's disease or atypical Parkinson's syndromes 2. Dementia with relevant displaying behavioural problems (neuropsychiatric Inventory; NPI, Subscore ≥ 8) 3. Depressive episodes (Geriatric Depression Scale, GDS (short version) ≥ 6) 4. Mental disability 5. Home Based Occupational Therapy for Dementia within the last 6 months 6. Impairment of visual and/or acoustic cognition which does not allow Occupational Therapy 7. Apoplexy with movement disorders which does not allow Occupational Therapy 8. Severe physical/systemic illnesses (cardio-pulmonal, Hematological or metabolic) which do not allow participating 9. Recent history of addictive disorder 10. Intermittent intake of depressant medication, that likely causes an impairment of cognitive performance during the trial 11. Participation in another clinical trial

Design outcomes

Primary

Measure	Time frame
Alzheimer's Disease Cooperative Study/Activities of Daily Living	2 weeks, 3 and 6 months after invention or 9, 19 and 31 weeks after randomization (treatment-as-usual-group)

Secondary

Measure	Time frame
- for patients: cognitive performance, displaying behavioural problems, satisfaction with occupational therapy, costs of occupational therapy - for family care givers: burden, medical condition, life-satisfaction	2 weeks, 3 and 6 months after invention or 9, 19 and 31 weeks after randomization (treatment-as-usual-group)

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026